Skip to main content
OpenTrials
Completed

NCT Number: NCT04022954

HD Mapping of Atrial Fibrillation in Asia Pacific

The aim of this study is to quantify and characterize the outcomes of radiofrequency (RF) ablation after, and the utility of, electroanatomical mapping with the market-released HD mapping catheters Inquiry™ AFocusII™ Double Loop and Advisor™ HD Grid, Sensor Enabled™ with the EnSite Cardiac Mapping System and the EnSite Automap module in subjects with AF in the real-world environment of the Asian population.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Sir Run Run Shaw Hospital, Hangzhou, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject must provide written informed consent for study participation and willing and able to comply with the protocol described evaluations and follow up schedule
  • Subject must be over 18 years of age. (In Japan, the subject must be of 20 years of age or older)
  • Subject is diagnosed with AF as defined by:
  • Documented symptomatic paroxysmal AF defined as AF that terminates spontaneously or with intervention within 7 days of onset
  • Documented symptomatic persistent AF defined as continuous atrial fibrillation that is sustained beyond 7 days but less than 12 months
  • Subject is indicated for cardiac electroanatomical mapping and RF ablation procedure to treat AF
  • Subject is planned to have electroanatomical mapping performed with the HD mapping catheters under investigation

Exclusion criteria

  • Previous ablation or surgery in the left atria
  • Implanted left atrial appendage occluder
  • Implanted mitral or tricuspid valve replacement
  • Implanted cardiac defibrillator (ICD)
  • Participation in another clinical investigation that may confound the results of this study
  • Pregnant or nursing
  • Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.
  • Life expectancy less than 12 months

Treatment and study plan

Catheter ablation

Device

Inquiry AFocusII Double Loop and Advisor HD Grid, Sensor Enabled

Primary outcomes

  1. Number of Participants With Acute Success of RF Ablation After Electroanatomical Mapping With HD Mapping Catheters.

    Time frame: End of Procedure

    The rate of acute success was defined as the proportion of subjects who receive HD mapping and RF energy delivery resulting in acute termination of clinical arrhythmia, defined by termination to SR (or AT if being treated for PersAF) or non-inducibility of clinical arrhythmia after ablation (cardioversion allowed prior to inducibility attempt). This measure is presented here as the number of participants with acute success, and the associated percentage of subjects (proportion * 100%) with acute success is also displayed as the result of an automatic calculation.

  2. Number of Participants With Clinical Long-Term Success

    Time frame: 12 months post-procedure

    Freedom from all atrial arrhythmias (AF/AFL/AT) greater than 30 seconds (as documented by 24-hr Holter at 12-month follow-up) and on or off class I/III AADs. This measure is presented here as the number of participants, and the associated percentage of subjects (proportion * 100%) is also displayed as the result of an automatic calculation.

  3. Number of Participants With AAD-Free Long-Term Success

    Time frame: 12-month post-procedure

    Freedom from all atrial arrhythmias (AF/AFL/AT) greater than 30 seconds (as documented by 24-hr Holter at 12-month follow-up) and off all class I/III AADs. This measure is presented here as the number of participants, and the associated percentage of subjects (proportion * 100%) is also displayed as the result of an automatic calculation.

Secondary outcomes

  1. Overall Procedure Time

    Time frame: During Procedure

    Defined as time from initial catheter insertion to final catheter removal. This is one measure of the amount of time it took for the physician to use invasive tools (catheters) during the procedure to investigate, diagnose, and treat the participant's heart condition.

  2. Radiofrequency (RF) Time

    Time frame: During Procedure

    Defined as duration of time radiofrequency energy is delivered. This is a measure the amount of time the physician was actively applying treatment to the heart to treat the participant's heart condition.

  3. Fluoroscopy Time

    Time frame: During Procedure

    Defined as total time subject is exposed to fluoroscopy. Fluoroscopy is a type of medical imaging that uses x-rays. This imaging is used by the physician to facilitate a safe and effective procedure. Less fluoroscopy time may help reduce the risk of issues related to x-ray exposure, however other factors such as fluroscopy intensity (not measured in this study) may also be important.

  4. Mapping Time Associated With Mapping Arrhythmia

    Time frame: During Procedure

    Defined as the total cumulative mapping time and mapping time for the creation of each map (including any new or retrospective map created with Manual, AutoMap, and TurboMap mapping). As part of an ablation procedure to treat atrial fibrillation, some physicians create a map of the heart's electrical activity. The information in the map may be used by the physician to plan the treatment strategy. Mapping time provides a measure of how much time the physician spent creating, updating, and analyzing maps during the procedure. A short mapping time is not necessarily better or worse than a long mapping time, as other factors such as the amount and type of information gathered may also affect how useful the map is to the physician.

  5. Number of Mapping Points Collected

    Time frame: During Procedure

    Defined as total number of mapping points collected for the creation of each map. As part of an ablation procedure to treat atrial fibrillation, some physicians create a map of the heart's electrical activity. The information in the map may be used by the physician to plan the treatment strategy. Number of mapping points collected is a measure of how much information was collected. A small number of mapping points collected is not necessarily better or worse than a large number of points, as other factors such as the amount of time spent and type of information gathered may also affect how useful the map is to the physician.

  6. Number of Mapping Points Used

    Time frame: During Procedure

    Defined as the total number of mapping points used in each map. As part of an ablation procedure to treat atrial fibrillation, some physicians create a map of the heart's electrical activity. The information in the map may be used by the physician to plan the treatment strategy. Number of mapping points collected is a measure of how much information was collected, while number of mapping points used is a measure of how many such points were considered useful. A small number of mapping points used is not necessarily better or worse than a large number of points, as other factors such as the amount of time spent and type of information gathered may also affect how useful the map is to the physician.

  7. Number of Used Mapping Points Per Minute

    Time frame: During Procedure

    Defined as the total number of mapping points used divided by the relative mapping time. As part of an ablation procedure to treat atrial fibrillation, some physicians create a map of the heart's electrical activity. The information in the map may be used by the physician to plan the treatment strategy. Mapping time is a measure of how much time the physician spent collecting, updating, and analyzing the information in the map. Number of mapping points collected is a measure of how much information was collected, while number of mapping points used is a measure of how many such points were considered useful. The number of used mapping points per minute is a measure of how efficient the mapping process is. A larger number of used mapping points per minute may be associated with a more efficient mapping process. Mapping efficiency may be of interest to a physician, however other factors such as the type of information gathered may also be of interest.

  8. Substrate Characteristics Identified

    Time frame: During Procedure

    For each type of arrhythmogenic substrate this will be defined as the frequency of substrate type identified in cases that attempted to identify the specific substrate. As part of an ablation procedure to treat atrial fibrillation, some physicians create a map of the heart's electrical activity or use other tests to characterize the state, function, or health of certain areas of the heart tissue, and to localize certain areas that may be problematic (substrate). These localized characteristics may provide information to the physician that could be used to treat the participant's heart condition. This outcome measure lists common substrate characteristics and the number of subjects for which the characteristic was found or otherwise used as part of the treatment plan.

  9. Ablation Strategy(s) Used

    Time frame: During Procedure

    Defined by both the type of map used to define ablation strategy and the frequency each ablation strategy/target was used by physicians. A physician may use one or more strategies to treat the participant's heart condition, including selectively burning (ablating) certain areas of the heart. This outcome measure lists common ablation strategies and the number of participants that received treatment based on each strategy.

Other outcomes

  1. Number of Participants With Adverse Events

    Time frame: through study completion, an average of 1 year

    Adverse events include any device-, procedure-, or death-related events

  2. Number of Subjects With Repeat Ablations

    Time frame: 12-months post-procedure

    Rate of repeat ablations was defined as proportion of subjects with an additional ablation procedure to treat indicated cardiac arrhythmia (outside blanking period, if applicable). This measure is presented here as the number of participants, and the associated percentage of subjects (proportion * 100%) is also displayed as the result of an automatic calculation.

  3. Change in Quality of Life (QoL): EQ-5D-5L VAS Score

    Time frame: 12-months post-procedure

    Defined as change in quality of life score assessed by the validated QoL survey, EQ-5D-5L. The EQ-5D-5L is a descriptive system comprised of five questions related to mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each question has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

    EQ-5D-5L EQ VAS scores range from 0 (worst) to 100 (best). A positive change indicates an improvement.

Sponsors and collaborators

Lead sponsor

Abbott Medical Devices

Industry

Registry information

Official study title

HD Mapping Observational Study - Asia Pacific

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Jul 17, 2019
Registry last updated
Mar 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.